WE CLAIM:

1. Use of an ActRIIA fusion protein in the manufacture of a medicament for the treatment or prevention of telangiectasia, wherein

(i) one or more doses of the ActRIIA fusion protein is to be administered to a patient in an amount of 0.3 mg/kg once every 3 weeks for a period of 24 weeks; and

(ii) if the patient shows one or more symptoms or risk factors for developing telangiectasia, one or more doses of the ActRIIA fusion protein is to be administered to the patient in an amount that is reduced by at least half of the amount of the dose of (i);

(a) wherein the ActRIIA fusion protein comprises

(b) (a) an ActRIIA polypeptide comprising an amino acid sequence that is at least 90% identical to an amino acid sequence corresponding to residues 30-110 of SEQ ID NO: 1;

(c) (b) an Fc domain of an immunoglobulin;

(c) a linker domain positioned between the ActRIIA polypeptide domain and the Fc domain of the immunoglobulin.

2. Use of an ActRIIA fusion protein in the manufacture of a medicament for the treatment or prevention of telangiectasia, wherein

(i) one or more doses of the ActRIIA fusion protein is to be administered to a patient in an amount of 0.3 mg/kg once every 3 weeks for 24 weeks;

(ii) if the patient shows one or more symptoms or risk factors for developing telangiectasia, skipping a dose, wherein the patient is not treated for 6 weeks after step (i); and

(iii) resuming the administration of one or more doses of the ActRIIA fusion protein to the patient in an amount of 0.3 mg/kg once every 3 weeks for at least 24 weeks

(d) wherein the ActRIIA fusion protein comprises

(e) (a) an ActRIIA polypeptide comprising an amino acid sequence that is at least 90% identical to an amino acid sequence corresponding to residues 30-110 of SEQ ID NO: 1;

(f) (b) an Fc domain of an immunoglobulin;

(c) a linker domain positioned between the ActRIIA polypeptide domain and the Fc domain of the immunoglobulin.

3. Use of an ActRIIA fusion protein in the manufacture of a medicament for the treatment or prevention of telangiectasia, wherein

(i) one or more doses of the ActRIIA fusion protein is to be administered to a patient in an amount of 0.3 mg/kg once every 3 weeks for a period of 24 weeks or less;

(ii) after step (i), one or more doses of the ActRIIA fusion protein is to be administered to the patient in an amount of 0.7 mg/kg once every 3 weeks for as long as the patient needs treatment; and

(iii) if the patient shows one or more symptoms or risk factors for developing telangiectasia, while receiving the dose of step (ii), one or more doses of the ActRIIA fusion protein is to be administered, wherein the dose is to be administered in an amount of 0.3 mg/kg once every 3 weeks until symptoms improve;

wherein the ActRIIA fusion protein comprises an amino acid sequence that is at least 90% identical to an amino acid sequence corresponding to residues 30-110 of SEQ ID NO: 1,thereby treating or preventing telangiectasia.

4. The use of claim 3, wherein step (iii) comprises administration of one or more doses of ActRIIA fusion protein to the patient in an amount of 0.3 mg/kg once every 3 weeks for at least 24 weeks.

5. The use of claim 3, wherein the patient is not treated with the ActRIIA fusion protein for a period of at least 2-6 weeks between step (ii) and step (iii).

6. The use of claim 3 or claim 5, wherein the patient is not treated with the ActRIIA fusion protein for a period of at least 3 weeks between step (ii) and step (iii).

7. The use of any one of claims 3-6, wherein, step (i) comprises administration of the dose to the patient for at least 3 weeks.

8. The use of any one of claims 3-7, wherein step (ii) comprises administration of the dose to the patient for at least 21 weeks.

9. The use of any one of claims 3-7, wherein step (ii) comprises administration of the second dose to the patient for at least 45 weeks.

10. The use of any one of claims 1-9, wherein the one or more symptoms of telangiectasia are selected from the group consisting of pain, itching, threadlike red marks on the skin, mucocutaneous telangiectases, gastrointestinal bleeding, lesions on the skin, epistaxis,

gingival bleeding, arteriovenous malformations, internal telangiectases, and red spots on the skin.

11. The use of any one of claims 1-10, wherein the risk factors for developing telangiectasia are selected from the group consisting of:

i. low BMP9 levels;
ii. low BMP10 levels;
iii. low VEGF levels;
iv. hereditary hemorrhagic telangiectasia (HHT); and
v. connective tissue disease (CTD).

12. The use of any one of claims 1-10, wherein the medicament alleviates or improves the severity of telangiectasia in the patient.

13. The use of any one of claims 1-12, wherein the medicament prevents the progression of telangiectasia in the patient.

14. The use of claim 2 or claim 3, wherein the step (iii) comprises withholding administration of the ActRIIA fusion protein until the telangiectasia improves to ≤ Grade 1.

15. The use of any one of claims 1-14, wherein the patient is to receive the medicament for the treatment of pulmonary hypertension.

16. The use of any one of claims 1-15, wherein the patient is to receive the medicament for the treatment of pulmonary arterial hypertension.

17. The use of any one of claims 1-16, wherein the ActRIIA polypeptide comprises an amino acid sequence that is at least 95% identical to an amino acid sequence corresponding to residues 30-110 of SEQ ID NO: 1.

18. The use of any one of claims 1-17, wherein the ActRIIA polypeptide comprises an amino acid sequence that is at least 95% identical to an amino acid sequence corresponding to residues 21-135 of SEQ ID NO: 1.

19. The use of any one of claims 1-18, wherein the ActRIIA polypeptide comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 2.

20. The use of any one of claims 1-19, wherein the ActRIIA polypeptide comprises an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO: 2.

21. The use of any one of claims 1-20, wherein the Fc domain of the immunoglobulin is an Fc domain of an IgG1 immunoglobulin.

22. The use of any one of claims 1-21, wherein the linker domain is selected from the group consisting of: TGGG (SEQ ID NO: 20), TGGGG (SEQ ID NO: 18), SGGGG (SEQ ID NO: 19), GGGGS (SEQ ID NO: 22), GGG (SEQ ID NO: 16), GGGG (SEQ ID NO: 17), and SGGG (SEQ ID NO: 21).

23. The use of any one of claims 1-22, wherein the ActRIIA fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 23.

24. The use of any one of claims 1-23, wherein the ActRIIA fusion protein comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 23.

25. The use of any one of claims 1-23, wherein the ActRIIA fusion protein comprises the amino acid sequence of SEQ ID NO: 23.

26. The use of any one of claims 1-25, wherein the ActRIIA fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 40.

27. The use of any one of claims 1-24, wherein the ActRIIA fusion protein comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 40.

28. The use of any one of claims 1-24, wherein the ActRIIA fusion protein comprises the amino acid sequence of SEQ ID NO: 40.

29. The use of any one of claims 1-28, wherein the ActRIIA fusion protein is reconstituted following lyophilization.

30. The use of any one of claims 1-29, wherein the ActRIIA fusion protein is soluble.

31. The use of any one of claims 1-30, wherein the ActRIIA fusion protein is to be administered to the patient using subcutaneous injection.

32. The use of any one of claims 1-31, wherein the ActRIIA fusion protein is to be administered to the patient on a schedule selected from the group consisting of: every week, every 2 weeks, every 3 weeks, and every 4 weeks.

33. The use of any one of claims 1-32, wherein the ActRIIA fusion protein is part of a homodimer protein complex.

34. The use of any one of claims 1-33, wherein the ActRIIA fusion protein is glycosylated.

35. The use of any one of claims 1-34, wherein the ActRIIA fusion protein binds to one or more ligands selected from the group consisting of: activin A, activin B, and GDF11.

36. The use of claim 35, wherein the ActRIIA fusion protein further binds to one or more ligands selected from the group consisting of: BMP10, GDF8, and BMP6.

37. The use of any one of claims 1-36, wherein the patient is to be administered an additional active agent and/or supportive therapy.

38. The use of claim 37, wherein the additional active agent and/or supportive therapy is selected from the group consisting of: beta-blockers, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (ARBs), diuretic agents, lipid-lowering medications, endothelin blockers, PDE5 inhibitors, prostacyclins, and a left ventricular assist device (LVAD).

39. The use of claim 38, wherein the additional active agent and/or supportive therapy is selected from the group consisting of: prostacyclin and derivatives thereof (*e.g.*, epoprostenol, treprostinil, and iloprost); prostacyclin receptor agonists (*e.g.*, selexipag); endothelin receptor antagonists (*e.g.*, thelin, ambrisentan, macitentan, and bosentan); calcium channel blockers (*e.g.*, amlodipine, diltiazem, and nifedipine; anticoagulants (*e.g.*, warfarin); diuretics; oxygen therapy; atrial septostomy; pulmonary thromboendarterectomy; phosphodiesterase type 5 inhibitors (*e.g.*, sildenafil and tadalafil); activators of soluble guanylate cyclase (*e.g.*, cinaciguat and riociguat); ASK-1 inhibitors (*e.g.*, CIIA; SCH79797; GS-4997; MSC2032964A; 3H-naphtho[1,2,3-de]quiniline-2,7-diones, NQDI-1; 2-thioxo-

thiazolidines, 5-bromo-3-(4-oxo-2-thioxo-thiazolidine-5-ylidene)-1,3-dihydro-indol-2-one); NF-κB antagonists (*e.g.*, dh404, CDDO-epoxide; 2.2-difluoropropionamide; C28 imidazole (CDDO-Im); 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO); 3-Acetyloleanolic Acid; 3-Triflouroacetyloleanolic Acid; 28-Methyl-3-acetyloleanane; 28-Methyl-3-trifluoroacetyloleanane; 28-Methyloxyoleanolic Acid; SZC014; SCZ015; SZC017; PEGylated derivatives of oleanolic acid; 3-O-(beta-D-glucopyranosyl) oleanolic acid; 3-O-[beta-D-glucopyranosyl-(1-->3)-beta-D-glucopyranosyl] oleanolic acid; 3-O-[beta-D-glucopyranosyl-(1-->2)-beta-D-glucopyranosyl] oleanolic acid; 3-O-[beta-D-glucopyranosyl-(1-->3)-beta-D-glucopyranosyl] oleanolic acid 28-O-beta-D-glucopyranosyl ester; 3-O-[beta-D-glucopyranosyl-(1-->2)-beta-D-glucopyranosyl] oleanolic acid 28-O-beta-D-glucopyranosyl ester; 3-O-[a-L-rhamnopyranosyl-(1-->3)-beta-D-glucuronopyranosyl] oleanolic acid; 3-O-[alpha-L-rhamnopyranosyl-(1-->3)-beta-D-glucuronopyranosyl] oleanolic acid 28-O-beta-D-glucopyranosyl ester; 28-O-β-D-glucopyranosyl-oleanolic acid; 3-O-β-D-glucopyranosyl (1→3)-β-D-glucopyranosiduronic acid (CS1); oleanolic acid 3-O-β-D-glucopyranosyl (1→3)-β-D-glucopyranosiduronic acid (CS2); methyl 3,11-dioxoolean-12-en-28-olate (DIOXOL); ZCVI$_4$-2; Benzyl 3-dehydr-oxy-1,2,5-oxadiazolo[3',4':2,3]oleanolate); a left ventricular assist device (LVAD), and lung and/or heart transplantation.

40. The use of any one of claims 1-39, wherein the patient has been administered with one or more agents selected from the group consisting of: phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin receptor agonist, and endothelin receptor antagonists.

41. The use of claim 40, wherein the one or more agents is selected from the group consisting of: bosentan, sildenafil, beraprost, macitentan, selexipag, epoprostenol, treprostinil, iloprost, ambrisentan, and tadalafil.

42. The use of any one of claim 1-41, wherein the patient has been administered one or more therapies for PAH.